Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: Biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu

Bioconjugate Chemistry

Volumn 17, Issue 2, 2006, Pages 485-492

  Mohsin, Huma ^a   Jia, Fang ^a   Sivaguru, Geethapriya ^a   Hudson, Michael J ^b   Shelton, Tiffani D ^c   Hoffman, Timothy J ^c   Cutler, Cathy S ^a   Ketring, Alan R ^a   Athey, Phillip S ^d   Simón, Jaime ^d   Frank, R Keith ^d   Jurisson, Silvia S ^a   Lewis, Michael R ^a,c,e,f  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DOW CHEMICAL COMPANY   (United States)

^e University of Missouri   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; DISEASES; HYDROXYAPATITE; MAMMALS; STABILITY; TUMORS;

BIODISTRIBUTIONS; DECAY CHARACTERISTICS; HIGH SPECIFIC ACTIVITIES; HUMAN COLON; METHOXY; NUDE MICE; RADIOCHEMICAL PURITY; RADIOIMMUNOTHERAPY; RADIOLABELLING; TUMOR UPTAKE;

MONOCLONAL ANTIBODIES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIGEN; HOLMIUM 166; HYDROXYAPATITE; LANTHANIDE; LUTETIUM 177; METHOXY 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; MONOCLONAL ANTIBODY CC49; N HYDROXYSULFOSUCCINIMIDYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; PROMETHIUM 149; TAG 72 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CARCINOMA; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG LABELING; DRUG LIVER LEVEL; DRUG RETENTION; DRUG STABILITY; DRUG UPTAKE; EVALUATION; FEMALE; ISOTOPE LABELING; KIDNEY; MOUSE; NONHUMAN; NUDE MOUSE; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; SERUM; SPLEEN; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 33645465080     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0502356     Document Type: Article

References (37)

1. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., and Kaminski, M. S. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 18, 1316-1323.
2. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., and White, C. A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463.
3. Goldenberg, D. M. (2002) Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713.
4. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl. Med. Biol. 31, 213-223.
5. Lewis, M. R., Kao, J. Y., Anderson, A.-L. J., Shively, J. E., and Raubitschek, A. (2001) An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjugate Chem. 12, 320-324.
6. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5, 565-576.
7. 90Y-labeled DOTA and maleimido-cysteineamido- DOTA conjugated to chimeric anti-carcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems. Bioconjugate Chem. 9, 87-93.
8. Bryan, J. N., Jia, F., Mohsin, H., Sivaguru, G., Miller, W. H., Anderson, C. J., Henry, C. J., and Lewis, M. R. (2005) Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl. Med. Biol. 32, 851-858.
9. Bryan, J. N., Lewis, M. R., Henry, C. J., Owen, N. K., Zhang, J., Mohsin, H., Jia, F., Sivaguru, G., and Anderson, C. J. (2004) Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet. Comp. Oncol. 2, 82-90.
10. 64Cu for tumor imaging and therapy. J. Nucl. Med. 44, 1284-1292.
11. Muraro, R., Kuroki, M., Wunderlich, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J. (1988) Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 48, 4588-4596.
12. Battista, P., Muraro, R., Mammarella, S., Curia, M. C., Colasante, A., Rosini, S., Lesti, G., Sacco, R., French, D., Frati, L., and Costantini, R. M. (1990) Complementary reactivities of anticarcinoembryonic antigen and antitumor-associated glycoprotein 72 monoclonal antibodies in lung carcinomas. Cancer Res. 50, 6987-6994.
13. Johnston, W. W., Szpak, C. A., Thor, A., and Schlom, J. (1986) Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. Cancer Res. 46, 6462-6470.
14. Lyubsky, S., Madariaga, J., Lozowski, M., Mishriki, Y., Schuss, A., Chao, S., and Lundy, J. (1988) A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3. Am. J. Clin. Pathol. 89, 160-167.
15. Mazur, M. T., and Shultz, J. J. (1990) Prostatic adenocarcinoma. Evaluation of immunoreactivity to monoclonal antibody B72.3. Am. J. Clin. Pathol. 93, 466-470.
16. Nuti, M., Mottolese, M., Viora, M., Donnorso, P. R., Schlom, J., and Natali, P. G. (1986) Use of monoclonal antibodies to human breast tumor associated antigens in fine needle aspirate cytology. Int. J. Cancer 37, 493-498.
17. Nuti, M., Yoshio, A., Teramato, Y. A., Mariani-Costantini, R., Horan Hand, P., Colcher, D., and Schlom, J. (1982) A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 29, 539-545.
18. Ohuchi, N., Thor, A., Nose, M., Fujita, J., Kyogoku, M., and Schlom, J. (1986) Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. Int. J. Cancer 38, 643-650.
19. Stramignoni, D., Bowen, R., Atkinson, B. P., and Schlom, J. (1983) Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int. J. Cancer 31, 543-552.
20. Thor, A., Ohuchi, N., Szpak, C. A., Johnston, W. W., and Schlom, J. (1986) Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46, 3118-3124.
21. Xu, M., Real, F. X., Welt, S., Schussler, M. H., Oettgen, H. F., and Old, L. J. (1989) Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int. J. Cancer 44, 985-989.
22. Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L. S., Hinkle, G., and Siler, K. (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52, 1067-1072.
23. 177lutetium-labeled immunoconjugate. Cancer Res. 51, 2889-2896.
24. 177Lu-CC49: A phase I/II study. Gynecol. Oncol. 65, 94-101.
25. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., Kostakoglu, L., Schlom, J., and Larson, S. M. (1995) Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med. 36, 586-592.
26. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., and LoBuglio, A. F. (1996) Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37, 1491-1496.
27. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1, 1447-1454.
28. 131I-CC49 in colorectal cancer. Cancer 73, 1057-1066.
29. Tempero, M., Leichner, P., Dalrymple, G., Harrison, K., Augustine, S., Schlom, J., Anderson, J., Wisecarver, J., and Colcher, D. (1997) High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J. Clin. Oncol. 15, 1518-1528.
30. Sumerdon, G. A., Rogers, P. E., Lombardo, C. M., Schnobrich, K. E., Melvin, S. L., Hobart, E. D., Tribby, I.I. E., Stroupe, S. D., and Johnson, D. K. (1990) An optimized antibody-chelator conjugate for imaging of carcinoembryonic antigen with indium-111. Nucl. Med. Biol. 17, 247-254.
31. 64Cu-BAT-2IT-1A3. Cancer Biother. Radiopharm. 16, 483-494.
32. Li, W. P., Ma, D. S., Higginbotham, C., Hoffman, T., Ketring, A. R., Cutler, C. S., and Jurisson, S. S. (2001) Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl. Med. Biol. 28, 145-154.
33. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142, 68-78.
34. 90Y labeled DOTA analogs conjugated to B72.3 antibody. J. Nucl. Med. 45, 457P.
35. Guadagni, F., Roselli, M., Cosimelli, M., Spila, A., Cavaliere, F., Tedesco, M., Arcuri, R., Abbolito, M. R., Casale, V., Pericoli, M. N., Vecchione, A., Casciani, C. U., Greiner, J. W., and Schlom, J. (1996) Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res. 56, 5293-5298.
36. 177Lu. J. Labelled Compd. Radiopharm. 48, S21.
37. Kukis, D. L., Novak-Hofer, I., and DeNardo, S. J. (2001) Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother. Radiopharm. 16, 457-467.